News
TipRanks on MSN1d
AstraZeneca’s Phase III COPD Study: A Potential Game-Changer in Respiratory Treatment
AstraZeneca is conducting a Phase III study titled ‘A Randomized, Double-blind, Parallel Group, Multi-center, Phase III Study to Assess the Efficacy of Budesonide, Glycopyrronium, and Formoterol ...
India: Inhalation therapy remains a cornerstone in the treatment of obstructive, inflammatory, and infectious respiratory ...
Orbia Fluor & Energy Materials’ pharmaceutical business unit has published a new whitepaper about the industry’s ongoing transition to pressurised metered dose inhalers (pMDIs) to low global warming ...
MedPage Today on MSN3d
Inhaled GM-CSF Improves Lungs' Gas Exchange in Rare Autoimmune Condition
Inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) needed to clear lung surfactant improved ...
The Airsupra inhaler reduces severe asthma attacks by 47%, combining immediate relief with anti-inflammatory action.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback